ClearPoint Neuro, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. ClearPoint Neuro is a commercial-stage medical device company developing and commercializing platforms for minimally invasive brain procedures, alongside products and services supporting biologics and drug delivery research.
Financial performance
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Total revenue | $5.43 million | $5.03 million | +8% |
| Gross profit / gross margin | $3.20 million / 59% | $3.23 million / 64% | Margin down 5 percentage points |
| Operating loss | $5.71 million | $3.86 million | Loss widened |
| Net loss | $5.61 million | $3.96 million | Loss widened 42% |
| Net loss per share | $0.23 | $0.17 | Loss per share increased |
| Cash used in operating activities | $5.68 million | $4.27 million | Cash use increased |
Product revenue declined 17% to $2.63 million; service and other revenue rose 50% to $2.80 million. Biologics and drug delivery revenue grew 24% to $2.68 million, driven by services and license fees, while capital equipment and software revenue fell 38% to $0.40 million. Management attributed the lower gross margin primarily to overhead and inventory costs and higher biologics and drug delivery service costs.
At March 31, cash and cash equivalents were $21.79 million and short-term investments were $9.94 million, totaling $31.73 million. Cash and cash equivalents were $27.62 million at December 31, 2022. Total assets were $50.25 million and current liabilities were $6.05 million. The company reported $10 million principal outstanding on a secured convertible note, carried net at $9.91 million; it bears a floating rate, was 7.1% at quarter-end, and matures January 2025. The holder may convert at $6 per share, subject to adjustments.
Material changes and business developments
- Revenue growth was led by biologics and drug delivery services, including new pre-clinical trials and recognized license fees; disposable product revenue in that line declined.
- Sales and marketing expense increased 45% to $2.93 million, primarily due to added personnel and travel. General and administrative expense increased 36% to $2.96 million, including higher personnel costs and the allowance for credit losses. Research and development expense rose 4% to $3.02 million.
- The company reported more than 50 biologics and drug delivery partners, versus approximately 45 a year earlier.
- A Carlsbad office and manufacturing facility lease is scheduled to commence June 1, 2023, with total minimum lease payments of $5.1 million over its term.
Outlook, risks, and contingencies
No specific revenue or earnings guidance is provided. Management stated that existing cash, cash equivalents, and short-term investments are expected to fund operations and obligations for at least the next 12 months based on current forecasts. The company has incurred ongoing losses and expects it may continue to do so as it commercializes products and develops additional applications.
Management cited uncertainty around market adoption, partner clinical and commercial success, regulatory timelines, product development costs, supply-chain disruptions, inflation, labor availability, and access to capital. The company had $1.7 million in bank balances above FDIC-insured limits and warned that a financial institution failure could adversely affect liquidity. One related-party pharmaceutical customer accounted for 13% of Q1 2023 sales, compared with 19% in Q1 2022; the customer is also a stockholder and noteholder and has a board representative. The note’s LIBOR reference was due to be replaced by June 30, 2023; the filing does not specify the replacement benchmark. The company reported no legal proceedings expected to have a material adverse effect and no material changes to its previously disclosed risk factors apart from the deposit-risk disclosure.
Key facts for investors to verify
- Whether service and license-fee growth is recurring and can offset the decline in product and capital-equipment revenue.
- Cash burn, forecast assumptions, and the sufficiency of the $31.7 million in cash, cash equivalents, and short-term investments.
- The secured note’s post-LIBOR benchmark, resulting interest cost, and repayment or conversion plans.
- Progress in commercializing the Prism laser system and the new Carlsbad facility, including associated costs and execution risks.
- Customer concentration, partner trial progress, and exposure of cash deposits above FDIC insurance limits.